ChromaDex sides with FDA, pharma in NMN supplements debate – SupplySide Supplement Journal
ChromaDex sides with FDA, pharma in NMN supplements debate SupplySide Supplement Journal
AG-80308 for dry eye disease on track for Phase 2 clinical trial – Ophthalmology Times
AG-80308 for dry eye disease on track for Phase 2 clinical trial Ophthalmology Times
AG-80308 for dry eye disease on track for Phase 2 clinical trial – Ophthalmology Times Read Post »
Peptide Synthesis Market Size to Attain USD 1,438.78 Mn by 2035 – Precedence Research
Peptide Synthesis Market Size to Attain USD 1,438.78 Mn by 2035 Precedence Research
Peptide Synthesis Market Size to Attain USD 1,438.78 Mn by 2035 – Precedence Research Read Post »
Rational design of oral delivery nanosystems for hypoglycemic peptides – ScienceDirect.com
Rational design of oral delivery nanosystems for hypoglycemic peptides ScienceDirect.com
Combined computational modeling at different scales to understand peptide drug and excipient co-localization – Uppsala universitet
Combined computational modeling at different scales to understand peptide drug and excipient co-localization Uppsala universitet
New insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs – Wiley Interdisciplinary Reviews
New insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs Wiley Interdisciplinary Reviews
Startup Orbis Medicines Launches With €26M for Next-Generation Peptide Drugs – MedCity News
Startup Orbis Medicines Launches With €26M for Next-Generation Peptide Drugs MedCity News
Evaluation in pig of an intestinal administration device for oral peptide delivery – ScienceDirect.com
Evaluation in pig of an intestinal administration device for oral peptide delivery ScienceDirect.com
Found Technology to Overcome Poor Absorption Drawback of ‘Peptide’ Drugs – 아시아경제
Found Technology to Overcome Poor Absorption Drawback of ‘Peptide’ Drugs 아시아경제
Found Technology to Overcome Poor Absorption Drawback of ‘Peptide’ Drugs – 아시아경제 Read Post »
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist – PNAS
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist PNAS
Bile acid transporter-mediated oral drug delivery – ScienceDirect.com
Bile acid transporter-mediated oral drug delivery ScienceDirect.com
Bile acid transporter-mediated oral drug delivery – ScienceDirect.com Read Post »
Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients – National Institutes of Health (.gov)
Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients National Institutes of Health (.gov)